J Invest Surg:预用阿托品可以抑制麻醉期间芬太尼引起的咳嗽

2020-06-29 MedSci原创 MedSci原创

芬太尼和阿托品分别是用于麻醉诱导期间镇痛和预处理的药物。本研究旨在观察用于预处理的阿托品对麻醉诱导期间使用芬太尼时出现咳嗽的影响。

芬太尼和阿托品分别是用于麻醉诱导期间镇痛和预处理的药物。本研究旨在观察用于预处理的阿托品对麻醉诱导期间使用芬太尼时出现咳嗽的影响。

 

这是一项单盲、前瞻性、多臂、平行、随机的临床试验,纳入120例年龄在3~15岁之间的全身麻醉患者。患者被随机分为三组:对照组(C组)、阿托品组(A组)和利多卡因组(L组)。

 

结果显示,C组的咳嗽发生率为45%(n = 16),A组为16%(n = 6),L组为16%(n = 6)(P = 0.009)。A组有2例中度咳嗽,L组有2例中度咳嗽,而这些组中的其他病例均为轻度咳嗽。在C组中,7例为轻度咳嗽,6例为中度咳嗽,2例为重度咳嗽。

 

综上所述,该研究结果表明,在全麻诱导过程中,预用阿托品可以抑制芬太尼引起的咳嗽的发生率和严重程度。我们认为,由于阿托品具有抗毒蕈碱的作用,它与利多卡因一样,是一种有效的预用药。

 

原始出处:

 

Muhammet Emin Naldan, Zakir Arslan,et al., Comparison of Lidocaine and Atropine on Fentanyl-Induced Cough: A Randomized Controlled Study. J Invest Surg. 2019 Aug;32(5):428-432. doi: 10.1080/08941939.2018.1424272.  

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=945354, encodeId=03fb945354cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96e5446584, createdName=ms4000000720312734, createdTime=Thu Mar 04 09:15:03 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051574, encodeId=946620515e440, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun May 16 01:09:42 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645838, encodeId=25fb16458388a, content=<a href='/topic/show?id=418a9e82332' target=_blank style='color:#2F92EE;'>#阿托品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97823, encryptionId=418a9e82332, topicName=阿托品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fd723235219, createdName=陈吴1242, createdTime=Tue Aug 04 19:09:42 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384857, encodeId=5851138485e51, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jul 01 11:09:42 CST 2020, time=2020-07-01, status=1, ipAttribution=)]
    2021-03-04 ms4000000720312734

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=945354, encodeId=03fb945354cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96e5446584, createdName=ms4000000720312734, createdTime=Thu Mar 04 09:15:03 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051574, encodeId=946620515e440, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun May 16 01:09:42 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645838, encodeId=25fb16458388a, content=<a href='/topic/show?id=418a9e82332' target=_blank style='color:#2F92EE;'>#阿托品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97823, encryptionId=418a9e82332, topicName=阿托品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fd723235219, createdName=陈吴1242, createdTime=Tue Aug 04 19:09:42 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384857, encodeId=5851138485e51, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jul 01 11:09:42 CST 2020, time=2020-07-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=945354, encodeId=03fb945354cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96e5446584, createdName=ms4000000720312734, createdTime=Thu Mar 04 09:15:03 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051574, encodeId=946620515e440, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun May 16 01:09:42 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645838, encodeId=25fb16458388a, content=<a href='/topic/show?id=418a9e82332' target=_blank style='color:#2F92EE;'>#阿托品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97823, encryptionId=418a9e82332, topicName=阿托品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fd723235219, createdName=陈吴1242, createdTime=Tue Aug 04 19:09:42 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384857, encodeId=5851138485e51, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jul 01 11:09:42 CST 2020, time=2020-07-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=945354, encodeId=03fb945354cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a96e5446584, createdName=ms4000000720312734, createdTime=Thu Mar 04 09:15:03 CST 2021, time=2021-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051574, encodeId=946620515e440, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun May 16 01:09:42 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645838, encodeId=25fb16458388a, content=<a href='/topic/show?id=418a9e82332' target=_blank style='color:#2F92EE;'>#阿托品#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97823, encryptionId=418a9e82332, topicName=阿托品)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fd723235219, createdName=陈吴1242, createdTime=Tue Aug 04 19:09:42 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384857, encodeId=5851138485e51, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jul 01 11:09:42 CST 2020, time=2020-07-01, status=1, ipAttribution=)]
    2020-07-01 xue8602

相关资讯

Eur J Pediatr:肺音分析监测急性支气管炎患儿夜间咳嗽和喘息的时间过程

咳嗽和喘息是急性支气管炎的主要症状。迄今为止,对呼吸道症状的评价仅限于问卷调查等主观方法。本研究旨在客观地确定急性支气管炎患儿咳嗽和喘息的时间过程。

患者咳嗽、胸闷加重,居然是肝出了问题

患者,男,74岁。因「间断咳嗽、胸闷3年,加重5天」入院。

NEJM病例讨论:24岁男性发烧,咳嗽和呼吸困难,是新冠肺炎?

一名24岁的男子因发热、乏力、咳嗽、呼吸困难转入该院就诊。

社区获得性肺炎也能要命,治疗要快准狠!

患者男性,27岁, 5月2日急诊就诊。

患者咳嗽2年,近乎崩溃,最后一刻找到元凶

早些年,我在呼吸科病房呆过很长一段时间。

Chest:阿瑞匹坦作为晚期肺癌的咳嗽抑制剂

阿瑞匹坦使得晚期肺癌患者的咳嗽得到明显改善,并且不增加严重副作用。